Cytokinetics to Announce First Quarter Results on May 4, 2023
April 20, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2023 at 4:00...
Cytokinetics To Participate In The 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2023 it granted stock options to purchase an aggregate of...
Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis
March 31, 2023 07:30 ET
|
Cytokinetics, Incorporated
Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on Primary or Key Secondary Endpoints Cytokinetics to Host Conference Call and...
Cytokinetics Releases Inaugural Corporate Responsibility Report
March 27, 2023 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the release of its inaugural Corporate Responsibility Report, outlining the...
Cytokinetics to Participate in Upcoming Investor Conferences
March 06, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor...
Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session
March 04, 2023 10:00 ET
|
Cytokinetics, Incorporated
Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement to Phase 3 Additional...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28, 2023 it granted stock options to purchase an aggregate...
Cytokinetics Reports Fourth Quarter 2022 Financial Results
March 01, 2023 16:00 ET
|
Cytokinetics, Incorporated
Company Received Complete Response Letter from FDA for New Drug Application for Omecamtiv Mecarbil Data from Cohort 4 of REDWOOD-HCM to be Presented at the American College of Cardiology Scientific...
Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil
February 28, 2023 17:31 ET
|
Cytokinetics, Incorporated
Complete Response Letter States that GALACTIC-HF Alone Does not Establish Substantial Evidence of Effectiveness Sufficient for Approval Company Expects to Request Meeting with FDA to Discuss...